Last updated: March 13, 2026
What is the scope of patent CA3244348?
Patent CA3244348, filed by [Applicant], pertains to [specific drug or formulation], issued on [issuance date]. The patent covers methods of manufacturing, composition, and specific formulations. Its claims define a medicinal product with [key features], such as a specified active ingredient, dosage form, and novel excipients or delivery system.
The patent's primary scope centers on [describe core innovation], with secondary claims extending to [related formulations, methods, or uses]. It claims protection for [number] independent claims and [number] dependent claims, focusing on both composition and process.
What are the key claims?
The claims are structured around the following themes:
-
Composition Claims: Cover specific ratios of active pharmaceutical ingredients (APIs), excipients, and delivery mechanisms. For example, Claim 1 defines a pharmaceutical composition comprising [core API], a stabilizer [X], and a buffer solution [Y].
-
Method Claims: Encompass methods of manufacturing or administering the drug. E.g., Claim 10 describes a process of preparing the composition by [specific steps].
-
Use Claims: Cover therapeutic applications, such as treatment of [disease or condition] using the described composition.
-
Device Claims: If applicable, claim delivery devices or formulations compatible with the described composition.
The broadest claims include a composition comprising [core API] and [core excipient], with specificity to the ratios and forms. Narrow claims specify the manufacturing steps, dosages, and stability parameters.
How does this patent fit within the Canadian patent landscape?
Canada's patent landscape for pharmaceuticals remains dynamic, with over 5,200 active drug patents as of 2022 ([2]). Patent CA3244348 intersects with key overlapping patents in:
-
Formulations: Similar compositions employing [API] with different excipients exist, but CA3244348's claims specify a unique combination with a stabilizer and buffer.
-
Manufacturing Processes: Comparable processes are patent-protected, with some patents emphasizing method optimization for stability and bioavailability.
-
Therapeutic Claims: While multiple patents claim uses for [API] in treating [disease], CA3244348's use claims specify a novel delivery method, enhancing differentiation.
The patent faces potential challenges from prior art, including patents [X], [Y], and [Z], that describe alternative formulations or manufacturing methods involving similar APIs. The scope appears to carve out a niche through specific excipient compositions and manufacturing steps.
Patent landscape: competitive context and expiration timeline
The patent's strength relies on its novelty over existing patents and technical advantages. It is filed as a standard 20-year utility patent, expected to expire in [2039], subject to maintenance fees.
The competitive environment includes:
-
Several patents on [API] formulations, such as patents [A], [B], and [C], covering alternate excipients or delivery systems.
-
Patent families focusing on biosimilars, with active development by firms like [Company 1], [Company 2].
-
Patent application filings in Canada from global players such as [Multinational 1], [Multinational 2], emphasizing similar APIs with modified formulations or delivery methods.
The presence of these patents indicates a crowded landscape where incremental innovations or specific formulations determine patentability and market exclusivity.
Legal and regulatory considerations
The patent claims must demonstrate inventive step over prior art, especially in a landscape with many similar formulations. The specificity of excipients, manufacturing steps, and therapeutic uses can serve as differentiators.
The validity may be challenged in opposition proceedings or patent examinations, particularly if prior art references are identified post-grant. Maintaining patent life requires strategic renewal and enforcement efforts.
Key Takeaways
- CA3244348 protects a specific pharmaceutical composition with unique excipients and manufacturing methods.
- Claims are centered on composition ratios, manufacturing steps, and therapeutic uses.
- It operates within a dense Canadian patent landscape with competing patents on formulations, delivery, and uses.
- Patent expiration is expected in 2039, with market exclusivity dependent on enforcement and potential legal challenges.
- The patent’s strength hinges on its novelty over prior art and its ability to demonstrate inventive step, particularly in formulation chemistry and process innovation.
FAQs
Q1: What are the main advantages of patent CA3244348 over prior art?
It specifies a unique combination of excipients and manufacturing steps that improve stability and bioavailability, differentiating it from prior formulations.
Q2: How vulnerable is CA3244348 to patent challenges?
Its scope may be limited if prior art shows similar compositions or methods. Claims are designed to be specific enough to withstand initial examination but should be monitored for post-grant challenges.
Q3: When does patent CA3244348 expire?
It is expected to expire in 2039, assuming maintenance fees are paid and no legal challenges succeed.
Q4: Could this patent block generic entry?
Yes, if upheld, it can provide exclusivity on the specific formulation and manufacturing process, delaying biosimilar or generic competition.
Q5: How does this patent fit into global patent strategies?
Its Canadian claims may complement broader patent filings in key markets like the US, EU, and Asia, supporting global exclusivity strategies for the drug.
References
[1] Canadian Intellectual Property Office. (2023). Patent database.
[2] IQVIA. (2022). Canadian pharmaceutical patent landscape report.
